Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.52 |
| ▸ | SPR | P35270 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873821 | 0.90 | EPHX2 (0.58) | P2RX7SPREPHX2CYP2C9CYP2J2 | |
| SCHEMBL13873856 | 0.88 | EPHX2 (0.61) | P2RX7SPREPHX2CYP2C9CYP2J2 | |
| SCHEMBL13873840 | 0.85 | EPHX2 (0.62) | P2RX7EPHX2CYP2C9CYP2J2NAMPT | |
| SCHEMBL13873787 | 0.83 | SPR (0.54) | P2RX7SPREPHX2CYP2C9CYP2J2 | |
| SCHEMBL13873871 | 0.81 | EPHX2 (0.56) | P2RX7SPREPHX2CYP2C9CYP2J2 | |
| SCHEMBL13873638 | 0.79 | EPHX2 (0.81) | SPREPHX2CYP2C9CYP2J2NAMPT | |
| SCHEMBL13873854 | 0.78 | EPHX2 (0.67) | SPREPHX2CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL13873820 | 0.78 | CYP2C9 (0.53) | P2RX7SPREPHX2CYP2C9CYP2J2 | |
| SCHEMBL13873818 | 0.77 | EPHX2 (0.73) | SPREPHX2CYP2C9CYP2J2NAMPT | |
| SCHEMBL13873637 | 0.77 | CYP2C9 (0.57) | SPREPHX2CYP2C9CYP2J2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | P2RX7 1781/4885SPR 61/4885EPHX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.